Literature DB >> 8673090

Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families.

C M Phelan1, J M Lancaster, P Tonin, C Gumbs, C Cochran, R Carter, P Ghadirian, C Perret, R Moslehi, F Dion, M C Faucher, K Dole, S Karimi, W Foulkes, H Lounis, E Warner, P Goss, D Anderson, C Larsson, S A Narod, P A Futreal.   

Abstract

The hereditary breast cancer gene BRCA2 was recently cloned and is believed to account for almost half of site-specific breast cancer families and the majority of male breast cancer families. We screened 49 site-specific breast cancer families for mutations in the BRCA2 gene using single strand conformation analysis (SSCA) followed by direct sequencing. We found mutations in eight families, including all four families with male breast cancer. The eight mutations were small deletions with the exception of a single nonsense mutation, an all were predicted to interrupt the BRCA2 coding sequence and to lead to a truncated protein product. Other factors which predicted the presence of a BRCA2 mutation included a case of breast cancer diagnosed at age 35 or below (P = 0.01) and a family history of pancreatic cancer (P = 0.03). Two mutations were seen twice, including a 8535delAG, which was detected in two French Canadian families. Our results suggest the possibility that the proportion of site-specific breast cancer families attributable to BRCA2 may be overestimated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673090     DOI: 10.1038/ng0596-120

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  62 in total

1.  Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.

Authors:  B H Spain; C J Larson; L S Shihabuddin; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Inherited predisposition to pancreatic cancer.

Authors:  E Efthimiou; T Crnogorac-Jurcevic; N R Lemoine; T A Brentnall
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 3.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

4.  Role of BRCA1 and BRCA2 mutations in pancreatic cancer.

Authors:  Julia B Greer; David C Whitcomb
Journal:  Gut       Date:  2006-09-14       Impact factor: 23.059

5.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

6.  Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?

Authors:  O M Serova; S Mazoyer; N Puget; V Dubois; P Tonin; Y Y Shugart; D Goldgar; S A Narod; H T Lynch; G M Lenoir
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

7.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.

Authors:  A S Whittemore; G Gong; J Itnyre
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

Review 8.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

Review 9.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

10.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Authors:  P N Tonin; A M Mes-Masson; P A Futreal; K Morgan; M Mahon; W D Foulkes; D E Cole; D Provencher; P Ghadirian; S A Narod
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.